COSMO LADY (02298) obtained an additional 3.078 million shares from executive director Wu Xiaoli.
Urban Beauty (02298) announced that the company was informed by its Executive Director, Ms. Wu Xiaoli (Ms. Wu), that she had purchased a total of 3.078 million shares of the company's common stock on the market at an average price of approximately HK$0.366 per share between April 13, 2026 and April 15, 2026. These shares represent approximately 0.14% of the total issued share capital of the company as of the date of this announcement.
COSMO LADY (02298) announces that the company's executive director, Ms. Wu Xiaoli (Ms. Wu), has informed the company that she purchased a total of 3.078 million ordinary shares of the company in the market at an average price of approximately HK$0.366 per share from April 13, 2026 to April 15, 2026. These shares represent approximately 0.14% of the total issued share capital of the company as of the date of this announcement.
Ms. Wu is the spouse of Mr. Zheng Yaonan, the major shareholder and chairman and executive director of the company, and therefore Mr. Zheng is considered to have an interest in the shares held by Ms. Wu.
The company believes that Ms. Wu's recent increase in shareholding indicates her confidence in the future prospects of the company and its subsidiaries.
Related Articles

New stock news | Fylaland submits application to Hong Kong Stock Exchange for China's largest smart pool equipment supplier.

New stock news | Capital (601136.SH) submits a second application to the Hong Kong Stock Exchange, with total revenue exceeding 3.6 billion yuan in 2025.

Jiangsu Kanion Pharmaceutical (600557.SH) has received the approval notice for the clinical trial of Qingcan Tongluo Granules.
New stock news | Fylaland submits application to Hong Kong Stock Exchange for China's largest smart pool equipment supplier.

New stock news | Capital (601136.SH) submits a second application to the Hong Kong Stock Exchange, with total revenue exceeding 3.6 billion yuan in 2025.

Jiangsu Kanion Pharmaceutical (600557.SH) has received the approval notice for the clinical trial of Qingcan Tongluo Granules.

RECOMMEND

Hong Kong Hard‑Tech Companies Enhance Canton Fair Presence As Veterans And Newcomers Expand International Networks
17/04/2026

Thousand‑Fold Oversubscription In Hong Kong IPOs Signals Multiple Market Shifts
17/04/2026

Rising Compute Costs Drive Industry Price Increases As Institutions Expect Internet Firms To Outperform In Q1
17/04/2026


